{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:06:40Z","timestamp":1790356000245,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R56AG055479-01"],"award-info":[{"award-number":["1R56AG055479-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R37AG022102"],"award-info":[{"award-number":["R37AG022102"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40478-018-0585-2","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T07:11:42Z","timestamp":1534921902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice"],"prefix":"10.1186","volume":"6","author":[{"given":"Francesca","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Giliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Steslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Marambaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-4942","authenticated-orcid":false,"given":"Cristina","family":"d\u2019Abramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"issue":"1","key":"585_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.neurobiolaging.2012.05.010","volume":"34","author":"CM Acker","year":"2013","unstructured":"Acker CM, Forest SK, Zinkowski R, Davies P, d'Abramo C (2013) Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging 34(1):338\u2013350","journal-title":"Neurobiol Aging"},{"key":"585_CR2","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.1155\/2012\/980250","volume":"2012","author":"ZA Ahmad","year":"2012","unstructured":"Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M (2012) scFv antibody: principles and clinical application. Clin Dev Immunol 2012:980250","journal-title":"Clin Dev Immunol"},{"issue":"34","key":"585_CR3","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","volume":"27","author":"AA Asuni","year":"2007","unstructured":"Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27(34):9115\u20139129","journal-title":"J Neurosci"},{"issue":"4877","key":"585_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1126\/science.3140379","volume":"242","author":"RE Bird","year":"1988","unstructured":"Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM et al (1988) Single-chain antigen-binding proteins. Science 242(4877):423\u2013426","journal-title":"Science"},{"issue":"Pt 12","key":"585_CR5","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"D Boche","year":"2008","unstructured":"Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM et al (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131(Pt 12):3299\u20133310","journal-title":"Brain"},{"issue":"4","key":"585_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1471-4159.2011.07337.x","volume":"118","author":"A Boutajangout","year":"2011","unstructured":"Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118(4):658\u2013667","journal-title":"J Neurochem"},{"issue":"49","key":"585_CR7","doi-asserted-by":"publisher","first-page":"16559","DOI":"10.1523\/JNEUROSCI.4363-10.2010","volume":"30","author":"A Boutajangout","year":"2010","unstructured":"Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30(49):16559\u201316566","journal-title":"J Neurosci"},{"issue":"4","key":"585_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239\u2013259","journal-title":"Acta Neuropathol"},{"issue":"338","key":"585_CR9","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J et al (2016) Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med 8(338):338ra66","journal-title":"Sci Transl Med"},{"issue":"2","key":"585_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","volume":"10","author":"C Burger","year":"2004","unstructured":"Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10(2):302\u2013317","journal-title":"Mol Ther"},{"issue":"9","key":"585_CR11","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/mt.2008.148","volume":"16","author":"NC Carty","year":"2008","unstructured":"Carty NC, Nash K, Lee D, Mercer M, Gottschall PE, Meyers C et al (2008) Adeno-associated viral [AAV] serotype 5 vector mediated gene delivery of Endothelin-converting enzyme reduces A\u03b2 deposits in APP + PS1 transgenic mice. Mol Ther 16(9):1580\u20131586","journal-title":"Mol Ther"},{"issue":"12","key":"585_CR12","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1523\/JNEUROSCI.3192-13.2014","volume":"34","author":"DL Castillo-Carranza","year":"2014","unstructured":"Castillo-Carranza DL, Sengupta U, Guerrero-Mu\u00f1oz MJ, Lasagna-Reeves CA, Gerson JE, Singh G et al (2014) Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34(12):4260\u20134272","journal-title":"J Neurosci"},{"issue":"6","key":"585_CR13","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1038\/nprot.2006.450","volume":"1","author":"A Cetin","year":"2006","unstructured":"Cetin A, Komai S, Eliava M, Seeburg PH, Osten P (2006) Stereotaxic gene delivery in the rodent brain. Nat Protoc 1(6):3166\u20133173","journal-title":"Nat Protoc"},{"issue":"39","key":"585_CR14","doi-asserted-by":"publisher","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","volume":"286","author":"X Chai","year":"2011","unstructured":"Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H et al (2011) Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem 286(39):34457\u201334467","journal-title":"J Biol Chem"},{"issue":"20","key":"585_CR15","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","volume":"73","author":"CW Christine","year":"2009","unstructured":"Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA et al (2009) Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73(20):1662\u20131669","journal-title":"Neurology"},{"issue":"8","key":"585_CR16","doi-asserted-by":"publisher","first-page":"e0135774","DOI":"10.1371\/journal.pone.0135774","volume":"10","author":"C d\u2019Abramo","year":"2015","unstructured":"d\u2019Abramo C, Acker CM, Jimenez H, Davies P (2015) Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies. PLoS One 10(8):e0135774","journal-title":"PLoS One"},{"issue":"4","key":"585_CR17","doi-asserted-by":"publisher","first-page":"e62402","DOI":"10.1371\/journal.pone.0062402","volume":"8","author":"C d\u2019Abramo","year":"2013","unstructured":"d\u2019Abramo C, Acker CM, Jimenez HT, Davies P (2013) tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 8(4):e62402","journal-title":"PLoS One"},{"key":"585_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neurobiolaging.2015.09.017","volume":"37","author":"C d\u2019Abramo","year":"2016","unstructured":"d\u2019Abramo C, Acker CM, Schachter JB, Terracina G, Wang X, Forest SK et al (2016) Detecting tau in serum of transgenic animal models after tau immunotherapy treatment. Neurobiol Aging 37:58\u201365","journal-title":"Neurobiol Aging"},{"issue":"7","key":"585_CR19","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1073\/pnas.97.7.3428","volume":"97","author":"BL Davidson","year":"2000","unstructured":"Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA et al (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 97(7):3428\u20133432","journal-title":"Proc Natl Acad Sci U S A"},{"key":"585_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fimmu.2014.00082","volume":"5","author":"V Ferreira","year":"2014","unstructured":"Ferreira V, Petry H, Salmon F (2014) Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front Immunol 5:82","journal-title":"Front Immunol"},{"issue":"7662","key":"585_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ et al (2017) Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 547(7662):185\u2013190","journal-title":"Nature"},{"issue":"2","key":"585_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JAD-2012-121354","volume":"33","author":"SK Forest","year":"2013","unstructured":"Forest SK, Acker CM, d\u2019Abramo C, Davies P (2013) Methods for measuring tau pathology in transgenic mouse models. J Alzheimers Dis 33(2):463\u2013471","journal-title":"J Alzheimers Dis"},{"issue":"46","key":"585_CR23","doi-asserted-by":"publisher","first-page":"16129","DOI":"10.1523\/JNEUROSCI.2323-12.2012","volume":"32","author":"JL Furman","year":"2012","unstructured":"Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD et al (2012) Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 32(46):16129\u201316140","journal-title":"J Neurosci"},{"issue":"5","key":"585_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13346-011-0037-z","volume":"1","author":"CD Herzog","year":"2011","unstructured":"Herzog CD, Bishop KM, Brown L, Wilson A, Kordower JH, Bartus RT (2011) Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases. Drug Deliv Transl Res 1(5):361\u2013382","journal-title":"Drug Deliv Transl Res"},{"issue":"2\u20133","key":"585_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/08830189309061696","volume":"10","author":"JS Huston","year":"1993","unstructured":"Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F et al (1993) Medical applications of single-chain antibodies. Int Rev Immunol 10(2\u20133):195\u2013217","journal-title":"Int Rev Immunol"},{"issue":"5","key":"585_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1084\/jem.20162125","volume":"214","author":"C Ising","year":"2017","unstructured":"Ising C, Gallardo G, Leyns CEG, Wong CH, Stewart F, Koscal LJ et al (2017) AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med 214(5):1227\u20131238","journal-title":"J Exp Med"},{"issue":"6","key":"585_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/(SICI)1097-4547(19990315)55:6<713::AID-JNR6>3.0.CO;2-G","volume":"55","author":"GA Jicha","year":"1999","unstructured":"Jicha GA, Berenfeld B, Davies P (1999) Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res 55(6):713\u2013723","journal-title":"J Neurosci Res"},{"issue":"2","key":"585_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E","volume":"48","author":"GA Jicha","year":"1997","unstructured":"Jicha GA, Bowser R, Kazam IG, Davies P (1997) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res 48(2):128\u2013132","journal-title":"J Neurosci Res"},{"issue":"5","key":"585_CR29","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1046\/j.1471-4159.1997.69052087.x","volume":"69","author":"GA Jicha","year":"1997","unstructured":"Jicha GA, Lane E, Vincent I, Otvos L, Hoffmann R, Davies P (1997) A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem 69(5):2087\u20132095","journal-title":"J Neurochem"},{"issue":"1","key":"585_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D et al (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79(1):110\u2013119","journal-title":"Ann Neurol"},{"issue":"9579","key":"585_CR31","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus [AAV] borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369(9579):2097\u20132105","journal-title":"Lancet"},{"issue":"6","key":"585_CR32","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","volume":"16","author":"SH Lee","year":"2016","unstructured":"Lee SH, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H et al (2016) Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep 16(6):1690\u20131700","journal-title":"Cell Rep"},{"issue":"46","key":"585_CR33","doi-asserted-by":"publisher","first-page":"11923","DOI":"10.1523\/JNEUROSCI.2795-06.2006","volume":"26","author":"Y Levites","year":"2006","unstructured":"Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P et al (2006) Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 26(46):11923\u201311928","journal-title":"J Neurosci"},{"issue":"4","key":"585_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA LeWitt","year":"2011","unstructured":"LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN et al (2011) AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10(4):309\u2013319","journal-title":"Lancet Neurol"},{"issue":"49","key":"585_CR35","doi-asserted-by":"publisher","first-page":"12425","DOI":"10.1523\/JNEUROSCI.2016-16.2016","volume":"36","author":"W Liu","year":"2016","unstructured":"Liu W, Zhao L, Blackman B, Parmar M, Wong MY, Woo T et al (2016) Vectored Intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice. J Neurosci 36(49):12425\u201312435","journal-title":"J Neurosci"},{"issue":"12","key":"585_CR36","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks","year":"2010","unstructured":"Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N et al (2010) Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 9(12):1164\u20131172","journal-title":"Lancet Neurol"},{"issue":"5","key":"585_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/jgm.885","volume":"8","author":"SW McPhee","year":"2006","unstructured":"McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J et al (2006) Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 8(5):577\u2013588","journal-title":"J Gene Med"},{"issue":"18","key":"585_CR38","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"5","key":"585_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71(5):362\u2013381","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"585_CR40","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM (2012) Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 32(11):1959\u20131972","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"585_CR41","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","volume":"10","author":"MS Rafii","year":"2014","unstructured":"Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS et al (2014) A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement 10(5):571\u2013581","journal-title":"Alzheimers Dement"},{"issue":"7","key":"585_CR42","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","volume":"75","author":"MS Rafii","year":"2018","unstructured":"Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA et al (2018) Adeno-associated viral vector [serotype 2]-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial. JAMA Neurol 75(7):834\u2013841","journal-title":"JAMA Neurol"},{"issue":"1","key":"585_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/mt.2011.177","volume":"20","author":"K Rapti","year":"2012","unstructured":"Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, Zolotukhin S et al (2012) Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 20(1):73\u201383","journal-title":"Mol Ther"},{"issue":"4","key":"585_CR44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE et al (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9(4):363\u2013372","journal-title":"Lancet Neurol"},{"issue":"5","key":"585_CR45","doi-asserted-by":"publisher","first-page":"e0125614","DOI":"10.1371\/journal.pone.0125614","volume":"10","author":"S Sankaranarayanan","year":"2015","unstructured":"Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G et al (2015) Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 10(5):e0125614","journal-title":"PLoS One"},{"key":"585_CR46","doi-asserted-by":"publisher","first-page":"8490","DOI":"10.1038\/ncomms9490","volume":"6","author":"S Takeda","year":"2015","unstructured":"Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD et al (2015) Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nat Commun 6:8490","journal-title":"Nat Commun"},{"issue":"5","key":"585_CR47","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0197-4580(00)00157-3","volume":"21","author":"CL Weaver","year":"2000","unstructured":"Weaver CL, Espinoza M, Kress Y, Davies P (2000) Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging 21(5):719\u2013727","journal-title":"Neurobiol Aging"},{"key":"585_CR48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.03.004","volume":"69","author":"MS Weinberg","year":"2013","unstructured":"Weinberg MS, Samulski RJ, McCown TJ (2013) Adeno-associated virus [AAV] gene therapy for neurological disease. Neuropharmacology 69:82\u201388","journal-title":"Neuropharmacology"},{"issue":"1","key":"585_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/187152709787601858","volume":"8","author":"DM Wilcock","year":"2009","unstructured":"Wilcock DM, Colton CA (2009) Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets 8(1):50\u201364","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2\u20133","key":"585_CR50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0022-510X(82)90155-1","volume":"56","author":"GK Wilcock","year":"1982","unstructured":"Wilcock GK, Esiri MM (1982) Plaques, tangles and dementia. A quantitative study. J Neurol Sci 56(2\u20133):343\u2013356","journal-title":"J Neurol Sci"},{"issue":"5","key":"585_CR51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1006\/jmbi.2000.4265","volume":"305","author":"A W\u00f6rn","year":"2001","unstructured":"W\u00f6rn A, Pl\u00fcckthun A (2001) Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305(5):989\u20131010","journal-title":"J Mol Biol"},{"issue":"3","key":"585_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/acn3.176","volume":"2","author":"K Yanamandra","year":"2015","unstructured":"Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI et al (2015) Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol 2(3):278\u2013288","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"585_CR53","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","volume":"80","author":"K Yanamandra","year":"2013","unstructured":"Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE et al (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80(2):402\u2013414","journal-title":"Neuron"},{"issue":"3","key":"585_CR54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2174\/1566523054065039","volume":"5","author":"AK Zaiss","year":"2005","unstructured":"Zaiss AK, Muruve DA (2005) Immune responses to adeno-associated virus vectors. Curr Gene Ther 5(3):323\u2013331","journal-title":"Curr Gene Ther"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-018-0585-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40478-018-0585-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-018-0585-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T15:07:57Z","timestamp":1589555277000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-018-0585-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1186\/s40478-018-0585-2","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,22]]},"assertion":[{"value":"30 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"82"}}